The FDA has granted Fast Track designation to VS-041, an investigational therapy for the treatment of heart failure with preserved ejection fraction.
Scientists have directly measured the minuscule electron sharing that makes precious-metal catalysts so effective. Their new technique, IET, reveals how molecules bind and react on metal surfaces with ...
MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path ...
Clinical Trials Arena on MSN
MSD’s Phase II Cadence trial of Winrevair achieves primary goal
Cadence is a placebo-controlled, randomised, double-blind trial assessing Winrevair’s safety and efficacy in CpcPH patients.
Rahway, New Jersey Wednesday, November 19, 2025, 10:00 Hrs [IST] ...
Winrevair, which Merck has identified as a “growth driver,” significantly improved blood flow through the lungs to the heart ...
Merck , known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 2 CADENCE study evaluating WINREVAIRtm (sotatercept-csrk) in adults for the ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...
Get the latest on Tectonic Therapeutic, Inc.'s clinical progress in pulmonary hypertension and market potential. Click for ...
The study, which was simultaneously published in Circulation and presented as a Late-Breaking Clinical Trial at the American Heart Association Scientific Sessions, marked a significant step toward ...
NEW ORLEANS -- A polypill that combines three of the four mainstays of treatment for heart failure with reduced ejection ...
A once-daily polypill containing 3 guideline-directed therapies for heart failure with reduced ejection fraction (HFrEF) led ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback